Transgenic T Cell Therapy for AML in Adults
Official title: Transgenic T cell Therapy for Acute Myeloid Leukemia
Funded at Fred Hutchinson Cancer Center · NIH-11420378 · Data updated 2026-11-12
A patient-centered approach uses engineered autologous T cells to target AML in adults who may not be eligible for transplant.
Quick facts
| Grant type | P01 program project |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Fred Hutchinson Cancer Center NIH-funded |
| Lab location | 1 site (Seattle, United States) |
| Project start | August 28, 1997 |
| Project end | July 31, 2029 |
| Funding year | 2026 |
| Award (this year) | $957,908 |
| NIH project number | 5P01CA018029-50 |
| Project ID | NIH-11420378 on NIH RePORTER |
Who could benefit from this research
✓Could help
Adults with AML who are high-risk or not candidates for allogeneic transplantation.
✕Less likely to help
Patients whose AML does not express the WT1 target or who cannot tolerate cell therapy may not benefit.
What this research studies
This grant explores giving patients their own T cells that are modified to recognize a leukemia protein called WT1, aiming to attack AML without relying on donor transplants. The work builds on prior trials and seeks to improve persistence and effectiveness of the T cells in the body. If successful, patients could have a new, potentially less risky option to control or reduce leukemia cells while sparing healthy blood formation. The study involves laboratory and clinical steps to develop, test, and monitor these engineered cells in people with AML.
Why it matters
Potential benefit: It could lead to a powerful, patient-derived therapy that helps control AML and reduces the need for transplant-related risks.
How similar studies have gone: Previous WT1-targeted T cell therapies showed anti-leukemic activity and relapse prevention in early trials, but issues with durability and tumor escape remain.
Where this research is happening
-
Fred Hutchinson Cancer Center
Seattle, United States Active
Researchers
- Principal investigator: Chapuis, Aude — Fred Hutchinson Cancer Center
- Study coordinator: Chapuis, Aude
Related research
Other NIH-funded projects on the same topics.
-
Targeting the SCP4 pathway in acute myeloid leukemia (AML)
Aims to uncover how the SCP4 signaling pathway drives AML and how it could be blocked to help patients.
-
Interferon-γ plus donor immune cells to fight AML/MDS after partial donor transplant
This project tests a therapy that adds a signaling protein, IFN-γ, with donor immune cells to help treat relapsed AML/MDS after a haploidentical stem cell transplant.
-
Targeting the protein housekeeping system in adult leukemia
Researchers are testing a new approach to treat acute myeloid leukemia by disrupting how AML cells manage their proteins, with the goal of helping patients live longer and healthier lives.
-
Understanding how epigenetic helper proteins drive AML and how to target them
A scientist team is studying how accessory proteins in gene-regulating complexes affect acute myeloid leukemia and whether they can be targeted for safer, more precise therapies.
-
Targeting FLVCR1-enabled choline use in a aggressive AML subtype
A new approach aims to block how a specific leukemia subtype (CG-AML) takes up choline to feed its growth, potentially slowing or stopping the disease.
-
Advancing CD70-targeted CAR-NK Therapy for AML
A patient-focused look at a new cell therapy that uses engineered NK cells to target AML by hitting CD70, aiming to reduce relapse with potentially fewer blood cell problems.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.